Your browser doesn't support javascript.
loading
Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors.
Wu, Yanyu; Ren, Kaili; Wan, Yin; Lin, Huamao M.
Affiliation
  • Wu Y; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Wan Y; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Lin HM; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
J Oncol Pharm Pract ; 29(6): 1418-1427, 2023 Sep.
Article in En | MEDLINE | ID: mdl-36131505
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies Limits: Adult / Aged / Humans Country/Region as subject: America do norte Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies Limits: Adult / Aged / Humans Country/Region as subject: America do norte Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido